Sotagliflozin Versus Empagliflozin Added to Metformin for Glycemic Control in Type 2 Diabetes

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 140 participants.

Also called NCT07939750

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 140 participants (planned count) (from the registry)
Sponsor
Allied Hospital Faisalabad (from the registry)
Registry
  • NCT NCT07939750
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Pakistan (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07939750. Randomized; single masking; primary purpose treatment. Start 2026-12-01 (anticipated); primary completion 2027-12-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Sotagliflozin Versus Empagliflozin Added to Metformin for Glycemic Control in Type 2 Diabetes
Condition
Type 2 Diabetes Mellitus (DM)
Intervention (Drug)
Sotagliflozin
Intervention (Drug)
Empagliflozin (oral)
Intervention (Drug)
Metformin
Lead sponsor
Allied Hospital Faisalabad (class: other)

Record details

Record id
cardio:ct-nct07939750
Content hash
9a344812a9cd09423d6ded3554472c3afbd55c2ba7d424c31fc4f3725f05069d